GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why

About this update from Glaxosmithkline S.a.e.

GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio.The acquisition, announced on Tuesday, will give the British pharmaceutical giant access to three experimental lung cancer treatments, including two candidates currently under review by the US Food and Drug Administration and expected to receive regulatory decisions later this year.While the deal strengthens GSK’s long-term ambitions in oncology, investors appeared unconvinced by the scale and price of the transaction.GSK shares fell around 3% in early trading, making the stock one of the weakest performers on the FTSE 100, while Nuvalent shares surged nearly 38% in premarket trading in the United States.Premium offer for promising cancer assetsUnder the terms of the agreement, GSK will launch a cash tender offer of $124 per share for Nasdaq-listed Nuvalent, representing a roughly 40% premium to the company's closing price on Monday.Although the headline value of the transaction is $10.6 billion, GSK said its net investment would be approximately $9.4 billion after accounting for cash held on Nuvalent’s balance sheet.The acquisition provides GSK with access to two late-stage lung cancer drug candidates and a third earlier-stage asset, giving the company multiple opportunities in one of the pharmaceutical industry's most lucrative treatment areas.GSK expects the deal to contribute to revenue growth and strengthen core operating profit from next year.The company also said the acquisition would help cushion the impact of patent expirations for dolutegravir, a key HIV treatment, between 2028 and 2030.The transaction remains incremental to GSK’s broader target of generating more than £40 billion ($53.4 billion) in annual sales by 2031.Oncology remains central to growth strategyThe acquisition marks another step in GSK’s effort to rebuild its oncology business after exiting the sector more than a decade ago.In 2015, GSK completed a major asset swap with Swiss pharmaceutical company Novartis, selling its oncology division in exchange for Novartis’ vaccines business.The companies also merged their consumer healthcare operations, with GSK later buying out Novartis’ stake for $13 billion....

View stock analysis, news, and events for Glaxosmithkline S.a.e.